President and CEO Alison Moore outlined the company’s strategic focus on RNA medicines manufacturing at TD Cowen’s 46th ...
San Francisco-based biotechnology company Codexis has reported strong fourth-quarter and fiscal year 2025 financial results, with the company's focus on RNA medicine gaining significant momentum. In a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A spinout from George Church’s ...
Inside every cell, thousands of molecular signals collide, overlap, and compensate, obscuring the true drivers of gene expression. Scientists have now developed a way to silence that cellular noise, ...
From vaccines and diagnostics to emerging gene-based therapies, RNA molecules are now central to modern medicine. But as their use continues to grow, so does a fundamental challenge: producing RNA ...
A single enzyme that can generate all four nucleotide triphosphates, the building blocks of ribonucleic acid (RNA), was identified by researchers at the Institute of Science Tokyo. By using ...
From vaccines and diagnostics to emerging gene-based therapies, RNA molecules are now central to modern medicine. But as their use continues to grow, so does a fundamental challenge: producing RNA ...
The cold season is in full swing, throats are scratchy and noses are running. We feel ill and hope it is not the flu. The ...
Codexis has agreed to manufacture 50 grams of siRNA using its proprietary ECO Synthesis manufacturing platform to support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results